Eaglenos Overview
- Year Founded
-
2017
- Status
-
Private
- Employees
-
220
- Latest Deal Type
-
Series A
- Latest Deal Amount
-
$22M
- Investors
-
6
Eaglenos General Information
Description
Manufacturer of diagnostic devices designed to provide portable and precise health monitoring. The company's technology utilizes electrochemical sensing and microfluidics to offer blood gas biochemical analyzers, electrolyte analyzers, blood glucose meters, uric acid test strips, continuous glucose monitoring devices, and scanning electrochemical cell microscopes, enabling healthcare institutions and home users to access laboratory-grade diagnostic results through compact, maintenance-free systems.
Contact Information
Website
www.eaglenos.comCorporate Office
- Building B2-2
- Number 73 Tanmi Road, Jiangbei New District
- Nanjing, Jiangsu 210000
- China
Corporate Office
- Building B2-2
- Number 73 Tanmi Road, Jiangbei New District
- Nanjing, Jiangsu 210000
- China
Eaglenos Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 1. Later Stage VC (Series A) | 24-Feb-2023 | $22M | Completed | Generating Revenue |
Eaglenos Patents
Eaglenos Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2025214327-A1 | Dry film self-calibration sensing device and method for measuring concentration of analyte by dry film self-calibration sensing device | Pending | 12-Apr-2024 | ||
| WO-2025118453-A1 | Composite enzyme solution for total cholesterol detection, test paper and detection system | Inactive | 08-Dec-2023 | ||
| JP-2026534675-A | Inserter, implantable analyte monitoring device, and implantable analyte monitoring system | Pending | 20-Nov-2023 | ||
| AU-2024386634-A1 | Needle-assisting device, implantable analyte monitoring device, and implantable analyte monitoring system | Pending | 20-Nov-2023 | ||
| EP-4767935-A1 | Needle-assisting device, implantable analyte monitoring device, and implantable analyte monitoring system | Pending | 20-Nov-2023 | A61B5/14532 |
Eaglenos Signals
Eaglenos Investors (6)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| 3E Bioventures Capital | Venture Capital | Minority | ||
| 3E Bioventures (China) | Venture Capital | Minority | ||
| Grand Yangtze Capital | Venture Capital | Minority | ||
| Huatai Zijin Investment | Corporate Venture Capital | Minority | ||
| InnoMed Capital | Venture Capital | Minority |
Eaglenos Acquisitions (1)
Eaglenos’s most recent deal was a Merger/Acquisition with Novlead Biotech for . The deal was made on 06-Mar-2019.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Novlead Biotech | 06-Mar-2019 | Merger/Acquisition | Therapeutic Devices |
Eaglenos FAQs
-
When was Eaglenos founded?
Eaglenos was founded in 2017.
-
Where is Eaglenos headquartered?
Eaglenos is headquartered in Nanjing, China.
-
What is the size of Eaglenos?
Eaglenos has 220 total employees.
-
What industry is Eaglenos in?
Eaglenos’s primary industry is Diagnostic Equipment.
-
Is Eaglenos a private or public company?
Eaglenos is a Private company.
-
What is the current valuation of Eaglenos?
The current valuation of Eaglenos is .
-
What is Eaglenos’s current revenue?
The current revenue for Eaglenos is .
-
How much funding has Eaglenos raised over time?
Eaglenos has raised $22M.
-
Who are Eaglenos’s investors?
3E Bioventures Capital, 3E Bioventures (China), Grand Yangtze Capital, Huatai Zijin Investment, and InnoMed Capital are 5 of 6 investors who have invested in Eaglenos.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process